Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate and compare the stain build up of two stannous fluoride (SnF2) / sodium tripolyphosphate (STP) dentifrices of differing abrasivity levels, with a marketed standard fluoride dentifrice and a marketed SnF2 dentifrice.
This proof of principal (PoP) single centre, randomised, examiner blind, four-treatment arm, parallel design study will be used to evaluate and compare the stain buildup of two 0.454% SnF2/ 5% STP dentifrices of differing abrasivity levels, with a marketed standard fluoride dentifrice and a marketed SnF2 dentifrice. Stain will be assessed following a full professional dental prophylaxis, at intervals over a 4 week treatment period, using an established clinical measure of extrinsic dental stain - the MacPherson modification of the Lobene stain index (MLSI). Participants will be stratified by pre-prophylaxis MLSI score (total MLSI Area x Intensity (A×I) for the facial surfaces of the 12 anterior teeth) and smoking status. The study will be conducted in healthy participants with a propensity for extrinsic dental stain (in the opinion of the examiner) on the facial surfaces of the anterior teeth.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test dentifrice 1 (RDA~58) | Experimental | Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP. |
|
| Test dentifrice 2 (RDA~77) | Experimental | Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP. |
|
| Reference dentifrice 1 (RDA~80) | Other | Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP). |
|
| Reference dentifrice 2 (RDA~120) | Active Comparator | Participants will apply dentifrice containing 0.454% SnF2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica | Other | Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4 | An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI after usage of the allocated study dentifrice, after 4 weeks twice daily use. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score). | Baseline and Week 4 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Mississauga | Ontario | L4W 0C2 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34059275 | Derived | Mason S, Young S, Qaqish J, Frappin G, Goyal C. Stain control with two modified stannous fluoride/sodium tripolyphosphate toothpastes: A randomised controlled proof of concept study. J Dent. 2019;91S:100009. doi: 10.1016/j.jjodo.2019.100009. Epub 2019 Oct 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A total of 225 participants were screened, of which 220 participants were enrolled and randomized in the study. A total of 5 participants were not randomized in study as 3 participants did not meet study criteria, and 2 withdrew their consent.
Participants were recruited from one center in Canada.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Test Dentifrice 1 (RDA~58) | Participants applied experimental dentifrice containing 0.454 percent (%) stannous fluoride (SnF2) / 5% sodium tripolyphosphate (STP); 2.0% abrasive silica |
| FG001 | Test Dentifrice 2 (RDA~77) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 30, 2017 | Jul 25, 2018 |
Not provided
Single centre, randomised, examiner blind, parallel design study to evaluate the buildup of extrinsic dental stain over a 4 week treatment period
Not provided
Not provided
Not provided
|
| Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%) | Other | Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate. |
|
| Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80 | Other | Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate. |
|
| Stannous fluoride (SnF2, 0.454%), RDA~120 | Other | Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate. |
|
Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica
| FG002 | Reference Dentifrice 1 (RDA~80) | Participants applied dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP) |
| FG003 | Reference Dentifrice 2 (RDA~120) | Participants applied dentifrice containing 0.454% SnF2 |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Test Dentifrice 1 (RDA~58) | Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica |
| BG001 | Test Dentifrice 2 (RDA~77) | Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica |
| BG002 | Reference Dentifrice 1 (RDA~80) | Participants applied dentifrice containing 1000 ppm fluoride as SMFP |
| BG003 | Reference Dentifrice 2 (RDA~120) | Participants applied dentifrice containing 0.454% SnF2 |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4 | An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI after usage of the allocated study dentifrice, after 4 weeks twice daily use. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score). | The Intent-To-Treat (ITT) population (N=219) included all participants who were randomized, received at least 1 dose of investigational product, and had at least 1 post-baseline efficacy evaluation and were reported by randomized treatment. | Posted | Mean | Standard Deviation | Score on a scale | Baseline and Week 4 |
|
|
|
|
Approximately 35 days (28+/- 2 days, maximum 30 days plus 5 days follow up after last use of study product.
Safety population (N=220) included all participants who were randomized and received at least one dose of investigational product and was reported by treatment received.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Test Dentifrice 1 (RDA~58) | Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica | 0 | 55 | 0 | 55 | 1 | 55 |
| EG001 | Test Dentifrice 2 (RDA~77) | Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica | 0 | 55 | 0 | 55 | 0 | 55 |
| EG002 | Reference Dentifrice 1 (RDA~80) | Participants applied dentifrice containing 1000 ppm fluoride as SMFP | 0 | 55 | 0 | 55 | 1 | 55 |
| EG003 | Reference Dentifrice 2 (RDA~120) | Participants applied dentifrice containing 0.454% SnF2 | 0 | 55 | 0 | 55 | 0 | 55 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| BACK INJURY | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| VULVOVAGINAL MYCOTIC INFECTION | Infections and infestations | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 | GSKClinicalSupportHD@gsk.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 15, 2017 | Jul 25, 2018 | SAP_001.pdf |
| ID | Term |
|---|---|
| D014002 | Tin Fluorides |
| C005692 | triphosphoric acid |
| C012980 | fluorophosphate |
| ID | Term |
|---|---|
| D005459 | Fluorides |
| D006858 | Hydrofluoric Acid |
| D017611 | Fluorine Compounds |
| D007287 | Inorganic Chemicals |
| D017971 | Tin Compounds |
| D002327 | Cariostatic Agents |
| D001697 | Biomedical and Dental Materials |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Week 4 |
|
| ANCOVA | From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate. | 0.0043 | Statistical significance set at 5% level | Mean Difference (Net) | -0.05 | 2-Sided | 95 | -0.08 | -0.02 | Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment. | Superiority |
| ANCOVA | From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate. | <.0001 | Statistical significance set at 5% level | Mean Difference (Net) | -0.08 | 2-Sided | 95 | -0.12 | -0.05 | Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment. | Superiority |
| ANCOVA | From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate. | <.0001 | Statistical significance set at 5% level | Mean Difference (Final Values) | -0.11 | 2-Sided | 95 | -0.15 | -0.08 | Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment. | Superiority |
| ANCOVA | From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate. | 0.0779 | Statistical significance set at 5% level | Mean Difference (Final Values) | 0.03 | 2-Sided | 95 | -0.00 | 0.06 | Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment. | Superiority |
| ANCOVA | From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate. | 0.0001 | Statistical significance set at 5% level | Mean Difference (Final Values) | 0.07 | 2-Sided | 95 | 0.03 | 0.10 | Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment. | Superiority |